Shared on 02 Nov 25
Fair value Increased 2.00%Glaukos’ analyst price target has risen to $119.85 from $117.50. Analysts cite robust quarterly results and increasing optimism over key growth drivers such as iDose and Epioxa.
Shared on 18 Oct 25
Fair value Decreased 2.61%Advancements In Ocular Therapies Will Transform Global Markets
Glaukos' analyst price target has been revised downward from $120.64 to $117.50. This reflects slightly tempered revenue growth and profit margin expectations, as analysts note ongoing reimbursement improvements and a positive long-term outlook for the company's iDose product despite recent share volatility.
Shared on 04 Oct 25
Fair value Decreased 1.49%Advancements In Ocular Therapies Will Transform Global Markets
Glaukos' analyst consensus price target has been revised slightly lower, from $122.46 to $120.64, as analysts cite near-term reimbursement bottlenecks. This is offset by improving sentiment surrounding the company's accelerating iDose trajectory and favorable long-term market positioning.
Shared on 01 May 25
Fair value Decreased 12%Advancements In Ocular Therapies Will Transform Global Markets
Shared on 24 Apr 25
Fair value Decreased 15%Launch Of iDose TR And Epioxa Will Transform Eye Treatments By 2025
AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.
Shared on 17 Apr 25
Fair value Decreased 5.54%Launch Of iDose TR And Epioxa Will Transform Eye Treatments By 2025
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 1.10%Launch Of iDose TR And Epioxa Will Transform Eye Treatments By 2025
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 4.43%Launch Of iDose TR And Epioxa Will Transform Eye Treatments By 2025
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Increased 37%Launch Of iDose TR And Epioxa Will Transform Eye Treatments By 2025
AnalystConsensusTarget made no meaningful changes to valuation assumptions.